- Home
- U vs JAZZ Comparison
U vs JAZZ Comparison
Compare U & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | U | JAZZ |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 10.4B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | U | JAZZ |
|---|---|---|
| Price | $42.35 | $168.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 16 |
| Target Price | $42.13 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 7.0M | 1.1M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,803,658,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $3.41 | $6.00 |
| Revenue Next Year | $13.76 | $6.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.14 |
| 52 Week Low | $15.33 | $95.49 |
| 52 Week High | $52.15 | $182.99 |
Technical Indicators
Market Signals| Indicator | U | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 53.11 |
| Support Level | $39.71 | $165.01 |
| Resistance Level | $46.09 | $171.70 |
| Average True Range (ATR) | 2.71 | 6.10 |
| MACD | -0.44 | 0.02 |
| Stochastic Oscillator | 29.60 | 66.15 |
Price Performance
Historical ComparisonAbout U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.